Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.74 |
| ▸ | CCR4 | P51679 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336067 | 0.90 | HSD11B1 (0.72) | HSD11B1CCR4NPSR1PTGER4MMP2 | |
| SCHEMBL12640543 | 0.89 | HSD11B1 (0.77) | HSD11B1CCR4NPSR1MMP2MMP8 | |
| SCHEMBL6336066 | 0.81 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL14529605 | 0.78 | ITGB1 (0.53) | HSD11B1MMP2 | |
| SCHEMBL5157584 | 0.76 | HSD11B1 (0.67) | HSD11B1 | |
| SCHEMBL6337638 | 0.73 | HSD11B1 (0.65) | HSD11B1 | |
| SCHEMBL5316746 | 0.73 | ITGB1 (0.50) | HSD11B1 | |
| SCHEMBL5157285 | 0.73 | HSD11B1 (0.55) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL5154827 | 0.72 | HSD11B1 (0.70) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL12610704 | 0.72 | ALDH1A1 (0.44) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | claimed |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | claimed |
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | claimed |
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | disclosed |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CCR4 4580/4885NPSR1 2743/4885 |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CCR4 4615/4885NPSR1 3019/4885 |
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CCR4 4580/4885NPSR1 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.